Evolus, Inc. Common Stock

EOLSNASDAQUSD
8.88 USD
0.10 (1.08%)🟢LIVE (AS OF 12:43 PM EDT)
🟢Market: OPEN

Shares of Evolus, Inc. Common Stock (EOLS) are trading at $8.88. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. Key drivers include a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (111.1%), a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation side, EOLS appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Aug 24, 2026.

Open?$8.72
High?$8.97
Low?$8.72
Prev. Close?$8.78
Volume?861.9K
Avg. Volume?927.0K
VWAP?$8.89
Rel. Volume?0.93x
Bid / Ask
Bid?$8.91 × 200
Ask?$8.93 × 100
Spread?$0.02
Midpoint?$8.92
Valuation & Ratios
Market Cap?579.9M
Shares Out?66.1M
Float?52.5M
Float %?79.7%
P/E Ratio?N/A
P/B Ratio?-18.77
EPS?-$0.52
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Employees
353
Market Cap
579.9M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2018-02-08
Address
520 NEWPORT CENTER DRIVE
NEWPORT BEACH, CA 92660
Phone: (949) 284-4555
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+2/3)
Medium-Term (Wave)? Bullish(+2/3)
Short-Term (Ripple)? Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
82
Short Sent.?
39
Piotroski F-Score?3/9Weak
Altman Z-Score?-1.21Distress
Confidence?51%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?10.61%High
Short Interest?5.6M
Days to Cover?8.7
Free Float52.5M
Avg Daily Volume637.4K
Settlement Date2026-07-31
Financial Health
Current Ratio?1.70Adequate
Quick Ratio?1.28Adequate
Cash Ratio?0.46Low
Debt/Equity?-6.05Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A
P/B?
S&P
97
-18.77CHEAP
P/S?
Peers
100
S&P
70
1.83CHEAP
P/FCF?
N/A
EV/EBITDA?
S&P
97
-101.8CHEAP
EV/Sales?
Peers
100
S&P
71
2.28CHEAP
Returns & Efficiency
ROE?
Peers
50
S&P
97
111.1%STRONG
ROA?
S&P
3
-13.8%WEAK
Cash Flow & Enterprise
FCF?$-20170000
Enterprise Value?$721.9M
Fundamentals ratios updated end of day